Avacta Group (AVCT)


Latest News

Avacta hails encouraging results from FIT Biotech collaboration

Avacta Group said a research collaboration with Finland's FIT Biotech had produced 'very encouraging' data relating to its...

Successful Outcome of Study with FIT Biotech

RNS Number: 7844O Avacta Group PLC 22 May 2018 22 May 2018 Avacta Group plc ("Avacta" or "the Group" or "the Company") Successful Outcome of "Gene Delivery" Collaboration with FIT Biotech Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits Avacta Group plc (AIM: AVCT), the develop...

Holding(s) in Company

RNS Number: 6341M Avacta Group PLC 30 April 2018 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Avacta Group PLC 1...

Avacta (AVCT): Commendable rate of progress

Hardman & Co Research Hardman & Co Research: Avacta (AVCT): Commendable rate of progress 17-Apr-2018 / 07:15 GMT/BST Hardman & Co Research: Commendable rate of progress Avacta is a pre-clinical biotechnology company and the proprietary owner of Affimer technology. Affimers represent a radical alternative to the established antibody technology, w...

All News

22-05-18Avacta hails encouraging results from FIT Biotech collaborationStockMarketWire
22-05-18Successful Outcome of Study with FIT BiotechRNS
30-04-18Holding(s) in CompanyRNS
17-04-18Avacta (AVCT): Commendable rate of progressRNS
16-04-18Avacta Group net losses widen as costs riseStockMarketWire
16-04-18Interim ResultsRNS
09-04-18Issue of EquityRNS
29-03-18Avacta to Present at Investor ForumRNS
29-03-18Directorate ChangeRNS
13-03-18Director Deals - Avacta Group PLC (AVCT)StockMarketWire
13-03-18Director/PDMR ShareholdingRNS
07-03-18Price Monitoring ExtensionRNS
08-02-18Summary of Capital Markets DayRNS
02-02-18Six AIM pharma shares on verge of breakthroughInteractive Investor
22-01-18Avacta and OncoSec to CollaborateRNS
18-01-18Result of Annual General MeetingRNS
18-01-18Avacta in line with market forecasts StockMarketWire
18-01-18AGM Business Update and Notice of ResultsRNS
15-01-18HardmanResearch: Affimer Drug Conjugates a realityRNS
15-01-18Avacta agrees development partnership with Glythera StockMarketWire
15-01-18Drug Development Partnership with GlytheraRNS
08-01-18Avacta to host capital markets day StockMarketWire
08-01-18Capital Markets Day NotificationRNS
04-01-18PDMR Dealing and Issue of EquityRNS
03-01-18Avacta CEO to present at Biotech ShowcaseStockMarketWire
03-01-18Presenting at the Biotech Showcase, San FranciscoRNS
18-12-17Issue of EquityRNS
04-12-17Avacta schedules AGMStockMarketWire
04-12-17Posting of Annual Report and Notice of AGMRNS
30-11-17Avacta sets up SIP, issues sharesStockMarketWire
30-11-17Issue of EquityRNS
15-11-17Covance to present Affimer data at forum says AvactaStockMarketWire
15-11-17Covance to Present Affimer Data at ConferenceRNS
14-11-17Holding(s) in CompanyRNS
13-11-17Avacta to present at PEGS EuropeStockMarketWire
13-11-17Avacta to present at PEGS EuropeRNS
13-11-17Avacta to Present at Investor EveningRNS
24-10-17Record Year for Affimers in scientific publications, says Avacta StockMarketWire
24-10-17Affimers in Scientific PublicationsRNS
19-10-17Private Shareholder Update EventRNS

RSS feeds

  • Editorial news feed for LSE:AVCT Editorial
  • Regulatory news feed for LSE:AVCT Regulatory